Human polyclonal immunotherapy platform shows broad potential to combat infectious disease SIOUX FALLS, S.D.-Thursday, January 11th 2018 [ AETOS Wire ] (BUSINESS WIRE) -- SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced its anti-MERS immunotherapy (SAB-301) appears safe in a Phase I Clinical Trial. Results of the study, sponsored, funded and conducted by National Institutes of Health (NIH) were published today in The Lancet Infectious Diseases. Presently, there are no approved vaccines or treatments for Middle East respiratory syndrome (MERS)–a newly discovered, contagious and sometimes fatal respiratory illness, caused by a virus known as MERS coronavirus (MERS-CoV). Since the first confirmed case in Saudi Arabia in 2012, the illness has spread to 27 countries and more than 2,000 people, with a fatality rate approaching 40%, according to the World Health Organization. “This is the first study to show the safety of a potential trea ... Read more »

Award is the first for Patient Safety Movement Foundation ranking system, which is being rolled out ORLANDO, Fla.-Thursday, January 11th 2018 [ AETOS Wire ] (BUSINESS WIRE) -- The Patient Safety Movement Foundation (PSMF) today awarded Florida-based Parrish Medical Center with the first-ever Patient Safety Five-Star Hospital ranking for implementing all 13 Actionable Patient Safety Solutions (APSS) – evidence-based processes designed to help hospitals eliminate preventable deaths and improve patient care. “We know that implementing all APSS, as a part of a comprehensive patient safety program, helps hospitals eliminate preventable deaths. We believe that by ranking the hospitals based on the number of APSS they have implemented is a good way to get to great results. We cannot hope for zero, we must plan for zero; and Parrish is indeed planning for zero,” said Joe Kiani, Founder of the Patient Safety Movement Foundation. Mr. Kiani continued, “We are incredibly proud of each comm ... Read more »

ZURICH-Thursday, January 11th 2018 [ AETOS Wire ] (BUSINESS WIRE) -- At the coming annual general meeting (AGM) on March 29, 2018, all ABB Board of Directors members will stand for reelection, with the exceptions of Ying Yeh and Louis R. Hughes, who have decided not to seek another term. Additionally, following a careful selection process, the Board of Directors has nominated three new candidates for seats on the board – Jennifer Xin-Zhe Li, former CFO of Baidu and current head of Baidu Capital, Geraldine Matchett, Global CFO of Royal DSM, and Gunnar Brock, the former President and CEO of Atlas Copco Group. The shareholders will vote on each candidate for election to the board at the AGM. “We are pleased to nominate Jennifer, Geraldine and Gunnar to ABB’s Board of Directors,” said Peter Voser, Chairman of the Board. “Each of these exceptional individuals brings relevant, long-term experience and judgment to the role. At the same time, I would like to thank Ying Yeh and Lou Hughes for ... Read more »

• Long-term collaboration will focus on scientific research in reproductive medicine that may lead to new treatments for fertility and pregnancy-related conditions • Dedicated joint institute will explore novel technologies in stem cell and regenerative medicine, and identify new targets for drug-discovery • Ferring and Chinese Academy of Sciences are both committed to addressing unmet needs in reproductive medicine and women’s health SAINT-PREX, Switzerland-Thursday, January 11th 2018 [ AETOS Wire ] (BUSINESS WIRE) -- Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic strategies. As part of the agreement, a new jointly funded laboratory will be created within the CAS research facility in Beijing, China. Known as the ‘Ferring Institute of Reproductive Medicine’, the facility will bring t ... Read more »